Clarient plays an increasingly important role in improving the lives of those affected by cancer. We are the leader in cancer diagnostics, dedicating ourselves to collaborative relationships with the healthcare community as we translate cancer discovery and information into better patient care.

We’re dedicated to bringing clarity to a complex disease by using a number of technologies and approaches to help our clients diagnose their cancer cases. We provide insight into what therapies will work best for patients, and continue with follow-up and monitoring on these cases. At Clarient, we pride ourselves by collaborating with our local pathologists and oncologists, because together—we are Taking Cancer Personally.

The cancer diagnostics marketplace has taken on a tremendous amount of change and will continue to do so in the foreseeable future. New technologies and applications are being developed at a record breaking pace. We pride ourselves by staying ahead of it. Our fully licensed state-of-the-art advanced cancer diagnostics laboratory provides full, comprehensive laboratory services that spans the full spectrum of cellular analysis, from protein identification by immunohistochemistry (IHC); to DNA and RNA analysis using molecular PCR and in situ hybridization; to cellular categorizing by flow cytometry.

We offer our clients a comprehensive test menu of anatomical pathology and molecular markers to not only help clients better diagnose and determine the best treatment plan for their patients, but also to help our local pathologists compete with larger institutions.

Clarient handles a significant amount of all breast cancer prognosis testing in the United States. By collaborating with our clients, our goal is to enable local pathologists and oncologists to deliver results—right in their own community.